reported here the low loading porphyrin-inspired high-valent manganese (IV)-oxo complex was applied in oxidative kineticresolution (OKR) of racemic heterocyclic sulfoxides using the environmentally benign hydrogen peroxide for the first time. This approach allows for rapid OKR (0.5 h) of a variety of racemic sulfoxides (including pyridine, pyrimidine, pyrazine, thiazole, benzothiazole, thiophene) in
Novel compounds and compositions as cathepsin inhibitors
申请人:Graupe Michael
公开号:US20070049594A1
公开(公告)日:2007-03-01
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
HAYASHI EISAKU; SHIMADA NORIAKI, YAKUGAKU DZASSI, J. PHARM. SOS. JAR. 1978, 98, NO 1, 95-99
作者:HAYASHI EISAKU、 SHIMADA NORIAKI
DOI:——
日期:——
PIPERIDINES AS MENIN INHIBITORS
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US20190152947A1
公开(公告)日:2019-05-23
The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R
2
, R
3a
, R
3b
, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
SMALL MOLECULE MENIN INHIBITORS
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US20210353610A1
公开(公告)日:2021-11-18
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R
1a
, R
1b
, R
1c
, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.